Particularly, CD229 was highly expressed in marginal-zone lymphomas (SMZL (87%), MALT (86%) and NMZ (82%) lymphomas) while heterogeneous expression was found in CLL (70%), MCL (70%), FL (60%) and DLBCL (GCB type 66% and non-GCB type (52%). Here, LY9 is linked to B-cell chronic lymphocytic leukemia.